68 results about "Bacteroides salyersiae" patented technology

The invention relates to a preparation method of bacteroides fragilis capsular polysaccharide A. The preparation method comprises the following steps: preparing a bacterial suspension of bacteroides fragilis with the pH value of less than or equal to 5, heating and extracting, and collecting an extracting solution to obtain a crude sugar solution of capsular polysaccharide A. Compared with the prior art, the preparation method has the following beneficial effects that the inventor accidentally finds that the capsular polysaccharide A can be effectively promoted to fall off from the bacteroides fragilis thalli by heating and extracting the bacteroides fragilis bacterial suspension of which the pH value is less than or equal to 5, so that the capsular polysaccharide A is extracted. Compared with a traditional phenol / water method, the capsular polysaccharide A can be obtained under the condition that phenol is not used, and the toxicity is low. Moreover, by adopting the preparation method, the yield of the bacteroides fragilis capsular polysaccharide A is obviously improved.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating acute radiation enteritis. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has a good preventing and treating effect to acute radiation enteritis, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis serving as probiotic can be used for preparing foods or medical compositions for preventing and treating acute radiation enteritis.

Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae, Propionibacterium acnes or any combination thereof. Also provided are processes for preparation of compounds described herein, pharmaceutical compositions thereof, and methods of treating bacterial infections.

The invention relates to the field of microbiological preparations, and particularly discloses an inactivated bacteroid micro-ecological preparation and a preparation method of the inactivated bacteroid micro-ecological preparation. The preparation uses inactivated bacteroid and fermentation concentrate as the main ingredients; and the inactivated bacterioid micro-ecological preparation has the efficacies of resisting bacteria, diminishing inflammation, adjusting the microbial community of the gastrointestinal tract, preventing gastrointestinal diseases of human and animals and the like, and has the characteristics of quick operation, high safety, use convenience and the like. The inactivated bacteroid micro-ecological preparation is used for disease prevention and health of human and animals, has a good practical application value, and has a remarkable effect especially when being applied to animal feeds, so that the probiotic inactivated micro-ecological preparation is a technology worth of population.

The invention discloses a bacteroides probiotic strain. The preservation number of the bacterial strain is CGMCC NO.17140, the preservation date is January 7, 2019, the bacterial strain is classifiedand named as bacteroides vulgaris, and the preservation unit is China General Microbiological Culture Collection Center. The bacterial strain is harmless to animals and has a remarkable effect of improving and regulating intestinal inflammation. The invention further discloses application of the bacterial strain in preparation of medicines and health care products for preventing and treating inflammatory bowel diseases.

The invention relates to a method for fermenting and producing fermented vinegar by using various probiotics. The method is characterized in that in an alcohol fermentation stage, cultured probiotics, which are suitable for the growth of amylase and yeast, of aspergillus niger, aspergillus oryzae and anaerobic bacteroides are added; in an acetic fermentation stage, cultured probiotics, which are suitable for the growth of acetic acid bacteria under 38-46 DEG C, of fermentation lactobacillus, lactobacillus lactic, lactobacillus plantarum, pediococcus acidilactici and bifidobacterium adolescentis are added for synergic fermentation, probiotics liquid vinegar obtained after the fermentation of the fermented vinegar is sterilized, and an appropriate amount of white granulated sugar is added to obtain the fermented vinegar with antioxidant substances. Vinegar residues can be dried to produce the filling materials of pig feed and animal feed. The method has the advantages that the material selection application range of probiotics culture media such as the aspergillus niger, aspergillus oryzae, anaerobic bacteroides, fermentation lactobacillus, lactobacillus lactic, lactobacillus plantarum, pediococcus acidilactici and bifidobacterium adolescentis is greatly widened, the novel fermented vinegar inactivated and fermented by the probiotics is provided for consumers, and the method is rich in raw material source, low in cost, stable in production process, low in production equipment investment, simple to operate, easy to popularize and promising in market application and development prospect.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The present invention discloses paenarthrobacter nicotinovorans and an application thereof in preventing and treating diseases. The microorganism group induction signal quenching bacterium paenarthrobacter nicotinovorans strain D-9 is screened and preserved at Guangdong Culture Collection Center on June 14, 2019, and has a preservation number of GDMCC No.60691. The strain has activity of quenchingquorum sensing signal molecules of N-acyl homoserine lactones (AHLs), besides has stable and significant quenching effect, and thus has huge application potential in preventing and treating harms ofpectobacterium carotovorum subsp. carotovora (Pcc) and other pathogenic bacteria mediated by depending AHLs quorum sensing signals. The anti-pathogenic drug with quorum quenching as a mode of action has broad application prospects.

The invention discloses bacteroides polymorphus GL-02, a complex microbial inoculant compounded by the bacteroides polymorphus GL-02 and bile acid and application of the complex microbial inoculant. The classification name of the bacteroides polymorphus GL-02 is bacteroides polymorphus thetaotomicron, the bacteroides polymorphus GL-02 is preserved in the China General Microbiological Culture Collection Center, and the preservation number of the bacteroides polymorphus GL02 is CGMCC No.20818. The bacterial colony of the strain is circular or quasi-circular, yellow, smooth and lusterless in surface, slightly convex in middle, opaque and neat in edge, and the diameter of the bacterial colony is 0.5-2.5 mm. The invention further provides a complex microbial inoculant prepared from the bacteroides polymorphus GL-02 bacterial powder and bile acid. The complex microbial inoculant can increase the milk yield and survival rate of cows in the lactation period, recover and can improve the metabolic function, material metabolism and liver function of the cows and promote growth of the calves of the cows.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating hypercholesteremia. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has good preventing and treating effect to hypercholesteremia, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis as probiotic can be used for preparing foods or medical compositions for preventing and treating hypercholesteremia so as to provide a clinically health-care and preventing and treating food suitable for human to take.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to an application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals. The invention explores a novel use of bacteroides fragilis and opens up a novel application field. Experiments show that bacteroides fragilis as a kind of probiotics can be used for preparing animal feed additives to prevent intestinal diseases of animals so as to promote healthy growth of animals.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating bacterial vaginitis. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect to treat bacterial vaginitis, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating bacterial vaginitis.

The invention relates to an application of bacteroides fragilis in the preparation of a composition for treating constipation. The bacteroides fragilis is used for preparing a carrier, and also can be used for preparing the composition of a food or a drug containing the microorganism. An experiment proves that the bacteroides fragilis has a good treatment effect on constipation; the bacteroides fragilis not only can supply physiological bacteria for an intestinal tract, corrects flora disturbance of the intestinal tract during constipation, and promotes digestive absorption of the food; various organic acids are also formed in the process of metabolization of the intestinal tract; and an acidic environment is built in the intestinal tract. Therefore, the pH value of the intestinal tract can be reduced; normal peristalsis of the intestinal tract is facilitated; meanwhile, spoilage organisms are inhibited; the adverse effect of harmful metabolites on the intestinal tract generated by the spoilage organisms of the intestinal track is reduced; enteroplegia is prevented; and the prepared drug is good in effect of treating the constipation, free of side effect, safe and reliable.

The invention provides a liquid-solid combined fermentation process for Bacteroides fragilis. The process comprises a first step of preparing a liquid nutrient solution from, by weight, 0.5 to 2.5% of peptone, 0.2 to 0.5% of glucose, 0.001 to 0.5% of cysteine, 0.2 to 0.5% of NaCl, 0.1 to 0.3% of NaHPO4, 0.02 to 0.1% of sodium thioglycolate, 30 to 60% of liquid ox liver extract, 30 to 60% of liquid beef extract and 0.1 to 0.8% of yeast extract. The process provided by the invention employs liquid-solid combined fermentation, and a great amount of Bacteroides fragilis can be obtained in a short period of time by using the process; and the process has the advantages of easiness, small investment, easy controllability in operation, small possibility of infection with competitors due to implementation of all the operations under vacuum and aseptic conditions and high concentration of bacterial strains.

The invention belongs to the biomedical field, in particular to the use of Bacteroides fragilis in the preparation of drugs for the treatment and prevention of tuberculosis. The invention also provides the application of Bacteroides fragilis in the preparation of pharmaceutical compositions, foods, health products and food additives for treating and / or preventing tuberculosis. The Bacteroides fragilis provided by the invention can effectively treat and / or prevent tuberculosis and enhance the immune protection effect of tuberculosis bacillus Calmette-Guerin vaccine (BCG), and has wide application prospect.

The invention discloses a strain of bacteroides vulgatus capable of protecting intestinal permeability and application thereof, and belongs to the technical field of microorganisms. The bacteroides vulgatus CCFM1152 provided by the invention has been preserved in the Guangdong Microbial Culture Collection Centre on November 9, 2020, and the preservation number is GDMCC No.61279. The bacteroides vulgatus CCFM1152 provided by the invention can effectively prevent weight loss and shortened colon length induced by DSS, reduce intestinal permeability and repair colonic mucosa injury. Therefore, the bacteroides vulgatus CCFM1152 has a wide application prospect in the aspect of preparing food and microecological preparations for protecting the intestinal permeability.

The invention discloses application of drug combination of bacteroides fragilis and a PD-1 antibody and / or a PD-L1 antibody in prevention and treatment of tumors of a genitourinary system. A large number of experiments prove that the bacteroides fragilis, especially the bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, can be used for effectively preventing and treating the tumors of the genitourinary system by regulating immune factors, improving the state of immune cells and enhancing the anti-tumor immune response of a body.

The invention relates to applications of Bacteroides fragilis in animal breeding, particularly to applications of Bacteroides fragilis in prevention and / or treatment of animal gastrointestinal diseases and in pharmaceutical compositions and feed additives, wherein the Bacteroides fragilis is ZY-312 and has the preservation number of CGMCC No.10685. According to the present invention, the Bacteroides fragilis ZY-312 does not contain the enterotoxin gene bft, has significant and high capabilities of cholate resistance and gastric acid resistance compared with the existing Bacteroides fragilis, can effectively prevent and / or treat animal gastrointestinal diseases, improves animal immunity and disease resistance, reduces animal prevalence, improves animal feed conversion rate, increases animal weight, promotes growth and development and production performance, can reduce the use of antibiotics, does not produce drug resistance, further has characteristics of safety and no toxicity, can improve the quality of products such as meat, eggs, milk and the like, can eliminate antibiotic drug residues, purify mew environment, and protects ecological environment.

The invention discloses an application of a bacteroides vulgarus probiotic strain in preparation of a lipid-lowering medicine. The strain is named as bacteroides vulgarus during preservation and is preserved in China General Microbiological Culture Collection Center on January 7, 2019, with an accession number being CGMCC No. 17140. The strain is harmless to animals, and has the blood fat regulating effects of remarkably reducing low-density lipoprotein, total cholesterol and triglyceride and increasing high-density lipoprotein.

The invention discloses a Bacteroides probiotic strain, the preservation number of which is CGMCC NO.17140, the preservation date is January 07, 2019, the preservation classification is named Bacteroides vulgaris, and the preservation unit is China Microbial Culture Collection Management Committee Center for General Microbiology. The bacterial strain is harmless to animals, and has the remarkable effect of improving and regulating intestinal inflammation. The invention also discloses the application of the bacterial strain in the preparation of medicines and health care products for preventing and treating inflammatory bowel disease.

The invention discloses application of drug combination of bacteroides fragilis zwitterionic capsular polysaccharide and a PD-1 antibody and / or a PD-L1 antibody in prevention and treatment of respiratory system tumors. A large number of experiments prove that the bacteroides fragilis zwitter-ion capsular polysaccharide, especially the zwitter-ion capsular polysaccharide extracted from bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, and the PD-1 antibody / PD-L1 antibody are combined for use, so that the immune cell proportion and the immune factor level can be adjusted, the anti-tumor immune response of a body is enhanced, and the respiratory system tumors are effectively prevented and treated.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides fmegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, or B7-2 inhibitor.

Proposed is an intestinal microbiome-improving composition containing ellagic acid as an active ingredient. The ellagic acid inhibits the growth of harmful bacteria such as Verrucomicrobia and Bacteroidetes attributable to alcohol intake and increases the growth of beneficial bacteria such as Firmicutes, thereby controlling intestinal microbes. As a result, the ellagic acid exhibits the effect of inhibiting an increase in a plasma endotoxin level, an increase in an intestinal TNF-α level, an increase in intestinal oxidative stress, a decrease in expression of intestinal TJ and AJ proteins, liver fat accumulation, an increase in plasma ALT, an increase in triglycerides, and hepatic oxidative stress and apoptosis. The composition containing ellagic acid as an active ingredient is provided as an intestinal microbe-improving composition and a preventive and therapeutic preparation for alcoholic fatty liver.

The invention discloses a strain composition for feed fermentation. The composition is prepared from the following strains in parts by weight: 12 to 18 parts of lactic acid bacteria, 15 to 25 parts of saccharomycetes, 3 to 8 parts of mould, 12 to 18 parts of bacillus, 8 to 12 parts of streptococcus, 4 to 6 parts of photosynthetic bacteria, 8 to 12 parts of bacteroides and 8 to 12 parts of trichoderma. The invention also provides a feed prepared from the fermentation strain composition. The strain composition has the advantages that nutritional ingredients in feed can be well converted into biological protein which can be easily absorbed by pigs, harmful strains and mosquitoes and flies can be inhibited from being generated, no antibiotic needs to be added, the disease resistance and disease prevention capacity of the pigs can be improved, and the meat quality of pork can be improved.

The invention relates to a novel application of Bacteroides fragilis and an immune checkpoint inhibitor. The invention relates to application of a combination of bacteroides fragilis and an immune checkpoint inhibitor in preparation of a medicine for preventing and treating lymphoma. The preservation number of the bacteroides fragilis is CGMCC No.10685. Compared with the prior art, the invention has the following beneficial effects: a large number of experiments prove that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 is combined with an immune checkpoint inhibitor for use, especially a PD-1 inhibitor for use, so that the Bacteroides fragilis ZY-312 has a synergistic effect on lymphoma.

The invention discloses a method for detecting influence of dietary fiber on activity of human intestinal bacteria in the field of bacterial activity detection. The method comprises the detection of bacteroides, and comprises the following specific steps: 1, preparing a bacteroides culture medium; 2, culturing the bacteroides until the bacteroides reaches a logarithmic phase, collecting the bacteroides, washing the bacteroides by using the bacteroides culture medium, and diluting bacteroides bacterial liquid by using the bacteroides culture medium until the OD600 value is 0.2 to 0.23; 3, in a96-pore plate, adding 100 microliters of diluted bacteroides bacterial liquid and 100 microliters of dietary fiber solution into each pore correspondingly, so that the bacterial concentration OD600 ineach pore is 0.09 to 0.11; culturing in a 37-DEG C constant-temperature anaerobic incubator for 72 hours, and recording the OD600 value every 12 hours; and 4, drawing a growth curve of the bacteroides under the action of the dietary fiber according to the OD600 value of the bacteroides recorded at each time point. According to the scheme, the bacteroides culture medium is optimized, so that the growth state of the bacteroides in the culture medium is more fit with the growth state of the bacteroides in a human intestinal tract, and the accuracy of a detection result is improved.

The invention discloses an aniline high-efficiency degradation microbial agent, a preparation method thereof and application of the aniline high-efficiency degradation microbial agent in chemical wastewater. The aniline high-efficiency degradation microbial agent mainly comprises alcaligenes faecalis, microbacterium bacteroides distasonis and lysine bacillus. The aniline degrading microbial agentcan grow by taking aniline as a unique carbon source and a unique nitrogen source, and can degrade 1000mg / L of aniline to 50mg / L or below, and the removal rate reaches 95% or above; the microbial agent prepared by the invention is added into wastewater according to a certain amount, contains a plurality of microorganisms with excellent degradation capability on aniline, and has a good degradationeffect on aniline polluted water, so that the problem that aniline is difficult to biologically solve is solved.

The invention discloses an anaerobic facultative probiotic symbiotic metabolic enzyme preparation. The preparation comprises the following components in parts by mass of 10-14 parts of clostridium which is a group of gram-positive bacteria and can generate spores, and the diameter of the spores is greater than the width of thalli, so that the thalli are expanded to be fusiform, and 12 to 18 partsof clostridium acetobutylicum, 12 to 18 parts of clostridium ljungdahlii, 12 to 18 parts of clostridium thermocellum, 8 to 12 parts of clostridium saccharobutyricum, 10 to 14 parts of clostridium septicum, 12 to 17 parts of frankia, 8 to 12 parts of salt-tolerant bacillus, 15 to 25 parts of bacteroides polymorphus, 15 to 22 parts of bacillus, 10 to 14 parts of streptomyces, 10 to 16 parts of ruminococcus, 12 to 18 parts of phosphokinase, 13 to 18 parts of acetyl coenzyme, 6 to 10 parts of acetyltransferase, 10 to 14 parts of phosphopyruvate hydratase, 10 to 15 parts of phosphodikinase, 11 to 18 parts of dehydrogenase, 10 to 14 parts of hydroxybutyryl coenzyme, 4 to 6 parts of hydroxybutyryl, 12 to 18 parts of acetyl, 12 to 18 parts of pyruvic acid, and 15-22 parts of phosphoric acid. The invention discloses a sludge treatment method. The preparation is simple to dewater in sludge treatment and degrades harmful substances, so that the sludge treatment is low in cost, pollution-free andlow in energy consumption.

The invention provides novel application of bacteroides fragilis zwitterionic capsular polysaccharide or / and modified zwitterionic capsular polysaccharide. Mainly relates to application of the capsular polysaccharide extract of bacteroides fragilis in preparation of anti-anxiety drugs, the preservation number of the bacteroides fragilis is CGMCC NO.10685, and the capsular polysaccharide extract is an extract of capsular polysaccharide A. The invention further relates to application of the capsular polysaccharide extract of bacteroides fragilis in preparation of anti-anxiety drugs. Compared with the prior art, the invention has the following beneficial effects: the inventor of the invention finds that the capsular polysaccharide A extract of Bacteroides fragilis ZY312 has an obvious effect on anxiety disorder, and the effect is verified by carrying out elevated cross maze behavioral determination and open field experiments on a rat model.

The invention discloses a probiotic candidate strain. The preservation number of the probiotic candidate strain is CGMCC NO.21251, the preservation date is November 26, 2020, the preservation classification name of the probiotic candidate strain is Bacteroides doreiXR2020 (B. dorei XR2020), and the preservation unit is China General Microbiological Culture Collection Center (CGMCC). The strain is harmless to animals and has a remarkable effect of improving clinical symptoms of influenza A. The invention further discloses application of the strain and thallus components thereof in preparation of drugs for preventing and treating influenza A.